Patents by Inventor Andrew David Whale

Andrew David Whale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT
    Publication number: 20230066999
    Abstract: The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.
    Type: Application
    Filed: March 1, 2022
    Publication date: March 2, 2023
    Inventors: Stephen Joseph Shuttleworth, Andrew David Whale
  • Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
    Patent number: 11291669
    Abstract: The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: April 5, 2022
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen Joseph Shuttleworth, Andrew David Whale
  • COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT
    Publication number: 20210069200
    Abstract: The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.
    Type: Application
    Filed: April 22, 2020
    Publication date: March 11, 2021
    Inventors: Stephen Joseph Shuttleworth, Andrew David Whale
  • COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS
    Publication number: 20200316062
    Abstract: The invention relates to a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of proteasome inhibitors, tumour immunotherapeutics or immunomodulatory agents, signal transduction pathway inhibitors, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.
    Type: Application
    Filed: June 5, 2017
    Publication date: October 8, 2020
    Inventors: Stephen Joseph Shuttleworth, Andrew David Whale, Lucy Mary Colman, Helen Louise Rogers
  • Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
    Patent number: 10668077
    Abstract: The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 2, 2020
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen Joseph Shuttleworth, Andrew David Whale
  • COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT
    Publication number: 20180243313
    Abstract: The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.
    Type: Application
    Filed: August 19, 2016
    Publication date: August 30, 2018
    Inventors: Stephen Joseph Shuttleworth, Andrew David Whale